Ruxolitinib- but not fedratinib-induced extreme thrombocytosis: the combination therapy with hydroxyurea and ruxolitinib is effective in reducing platelet count and splenomegaly/constitutional symptoms
Crossref DOI link: https://doi.org/10.1007/s00277-015-2397-9
Published Online: 2015-05-16
Published Print: 2015-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Polverelli, N.
Catani, L.
Vianelli, N.
Baccarani, M.
Cavo, M.
Palandri, F.
Text and Data Mining valid from 2015-05-16